NCT03317158 2026-04-15
ADAPT-BLADDER
Hoosier Cancer Research Network
Phase 1/2 Recruiting
Clinical Trials
21 trialsNCT04902040 2026-03-18
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT07332351 2026-03-13
TRIFECTA
University of Washington
Phase 2 Not yet recruiting
NCT06963346 2026-03-09
Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Suspended
NCT05137262 2026-02-18
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06263153 2025-12-17
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT03601455 2025-04-13
Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04106115 2024-12-04
DURANCE
University College, London
Phase 1/2 Recruiting
NCT03472274 2023-04-13
DUTRENEO
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase 2 Completed
NCT04543110 2023-03-23
RADIANT
Ottawa Hospital Research Institute
Phase 2 Unknown
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT02643303 2022-12-02
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT03773666 2022-09-13
A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02901548 2022-07-29
Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT03759496 2022-03-23
Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer
Hellenic GenitoUrinary Cancer Group
Phase 2 Unknown
NCT03430895 2021-12-01
Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04579133 2021-06-16
Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy
Latin American Cooperative Oncology Group
Phase 2 Terminated
NCT03824691 2021-02-25
ARCADIA
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT04073160 2020-07-07
TRIO Bladder
Duke University
Phase 1 Withdrawn
NCT03534492 2020-04-06
NEODURVARIB
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT03150836 2017-10-19
Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer
University of California, San Francisco
Phase 2 Withdrawn